PRAGUE, Czech Republic, June 15, 2020 / B3C newswire / -- SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial for the treatment of advanced solid tumors, in a virtual poster presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II being held from June 22-24, 2020.

Poster presentation details

A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.

Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the Phase 1 clinical trial.

About SOTIO SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. SOTIO is a registered trademark of SOTIO a.s. in selected countries.

Contacts

Company contact Richard Kapsa Head of Communication T: (+420) 224 174 448 M: (+420) 603 280 971 kapsa@sotio.com

Media contact Kirsten Frazer, Ph.D. LifeSci Communications T: +1 646-863-0222 kfrazer@lifescicomms.com

Keywords: Drug Evaluation, Preclinical; Medical Oncology; IL15 protein, human; Interleukin-15; CD8-Positive T-Lymphocytes;

Published by B3C newswire and shared through Newronic®

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.